Get started
Author

Simon McNamara

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2024 · Vania Hungria, Pawel Robak, et al. · New England Journal of Medicine · 214
Quality-Adjusted Life Expectancy Norms for the English Population
2022 · Simon McNamara, Paul P. Schneider, et al. · Value in Health · 108
PDF
How averse are the UK general public to inequalities in health between socioeconomic groups? A systematic review
2019 · Simon McNamara, John Holmes, et al. · The European Journal of Health Economics · 49
PDF
Drinking contexts and their association with acute alcohol‐related harm: A systematic review of event‐level studies on adults' drinking occasions
2020 · Abigail K. Stevely, John Holmes, et al. · Drug and Alcohol Review · 37
Does the UK-public's aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment
2020 · Simon McNamara, Aki Tsuchiya, et al. · Social Science & Medicine · 27
Socioeconomic inequalities in HRQoL in England: an age-sex stratified analysis
2022 · Paul Schneider, James Love-Koh, et al. · Health and Quality of Life Outcomes · 26
PDF
Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions
2023 · James Love-Koh, Paul Schneider, et al. · PharmacoEconomics · 23
PDF
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
2018 · D. Lee, A. Amadi, et al. · PharmacoEconomics - Open · 20
PDF
Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence
2024 · Monique A. Hartley‐Brown, Katja Weisel, et al. · British Journal of Haematology · 17
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
2025 · Meletios A Dimopoulos, Meral Beksac, et al. · The Lancet Haematology · 7
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
2025 · Vania Hungria, Marek Hus, et al. · The Lancet Haematology · 7
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
2025 · Francesca Gay, Elena Zamagni, et al. · Frontiers in Oncology · 7
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis
2025 · Shinsuke Iida, Yusuke Yasutomi, et al. · PLoS ONE · 5
PDF
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).
2024 · Vania Hungria, Pawel Robak, et al. · Journal of Clinical Oncology · 5
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma
2025 · Natalie Boytsov, Jasjit K. Multani, et al. · Future Oncology · 4
PDF
The Impact of Patient-Reported Adverse Events on Quality of Life: An Analysis of the Dreamm-7 and Dreamm-8 Randomized Controlled Trials
2024 · Angely Loubert, Laurine Bunod, et al. · Blood · 4
PDF
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis
2025 · Joshua Richter, Ajay Nooka, et al. · American Journal of Hematology · 3
Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey
2025 · Yusuke Yasutomi, Amanda Ribbands, et al. · Future Oncology · 3
P-362 A Real-World Study to Assess Treatment Patterns and Outcomes of Patients (pts) with 2L+ Relapsed or Refractory Multiple Myeloma in Italy, Germany, and the United Kingdom
2024 · Francesca Gay, K. Martin Kortüm, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis
2023 · Dawn Lee, Simon McNamara · Value in Health · 2
Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
2024 · Vania Hungria, Pawel Robak, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Testing The Utility Of The Nhs's Systemic Anti-Cancer Therapy Data Set For Multi-Indication Pricing
2014 · L. McNamara, S. McNamara · Value in Health · 1
PDF
Pcn97 a Cost-utility Analysis on the Use of Trastuzumab + Anastrozole Compared to Lapatinib + Letrozole, Letrozole Monotherapy or Anastrozole Monotherapy in the Treatment of Her2+/hormone Receptor Positive (hr+) Metastatic Breast Cancer (mbc) From the Perspective of the Uk National Health Service (nhs)
2010 · S McNamara, L Moore, et al. · Value in Health · 1
PDF
PA-296 Matching-Adjusted Indirect Comparison (MAIC) of Belantamab Mafodotin, Bortezomib, Dexamethasone (BVd) vs Carfilzomib, Lenalidomide, Dexamethasone (KRd) in Relapsed/Refractory Multiple Myeloma (RRMM)
2026 · Karthik Ramasamy, Rakesh Popat, et al. · Clinical Lymphoma Myeloma & Leukemia
Ee154 Impact of Using Relative Dose Intensity Versus Individual Patient Dosing: a Case Study Using Belantamab Mafodotin Data From the Dreamm-7 Study in Relapsed/refractory Multiple Myeloma
2026 · Yevgeniy SAMYSHKIN, Molly Purser, et al. · Value in Health
Works count: 49
Citation count: 573
H-index: 9
I10-index: 9
Year
Topic
Type